BusinessOcera to Announce Additional Encouraging Results from its Phase 2b STOP-HE Study of IV OCR-002 in Patients with Hepatic EncephalopathyBy Nasdaq OMXMar 8, 2017, 1:05 PM UTC
BusinessOcera to Present at the Cowen and Company 37th Annual Healthcare ConferenceBy Nasdaq OMXFeb 28, 2017, 9:05 PM UTC
BusinessGalectin Therapeutics Announces Achievement of Key Milestones Related to NASH-CX Clinical TrialBy Nasdaq OMXFeb 1, 2017, 1:10 PM UTC
BusinessOcera Announces Top-line Results for Phase 2b Study in Hepatic EncephalopathyBy Nasdaq OMXJan 30, 2017, 12:00 PM UTC
BusinessOcera Announces Successful Phase 1 Clinical Study of Orally-Administered OCR-002 in Patients with CirrhosisBy Nasdaq OMXJan 5, 2017, 2:05 PM UTC
BusinessGalectin Therapeutics Announces Positive New Psoriasis and Atopic Dermatitis Clinical Data, Seeking Strategic Partnerships for Therapy of Severe Skin DiseasesBy Nasdaq OMXNov 10, 2016, 1:00 PM UTC
BusinessOcera Therapeutics Reports Third Quarter 2016 Financial Results and Company UpdateBy Nasdaq OMXNov 2, 2016, 1:05 PM UTC
BusinessOcera Therapeutics Appoints Biopharmaceutical Veteran Willard Dere, M.D. to Board of DirectorsBy Nasdaq OMXOct 28, 2016, 1:05 PM UTC
